Inder Mainie
YOU?
Author Swipe
View article: Hemospray® (Hemostatic powder TC-325) as monotherapy for acute gastrointestinal bleeding: a multi-center prospective study
Hemospray® (Hemostatic powder TC-325) as monotherapy for acute gastrointestinal bleeding: a multi-center prospective study Open
Background Topical hemostatic powders are a reliable second-line approach in acute gastrointestinal (GI) bleeding (AGIB) treatment, according to the existing guidelines. Increasing evidence supports the use of hemostatic powder TC-325 (Hem…
View article: Hemospray® (hemostatic powder TC-325) as monotherapy for acute gastrointestinal bleeding: a multicenter prospective study
Hemospray® (hemostatic powder TC-325) as monotherapy for acute gastrointestinal bleeding: a multicenter prospective study Open
TC-325 monotherapy is safe and effective, especially in malignancy or post-endoscopic intervention bleeding. In patients with peptic ulcer, it could be helpful when the primary treatment is unfeasible, as bridge to definite therapy.
View article: Using Saliva Epigenetic Data to Develop and Validate a Multivariable Predictor of Esophageal Cancer Status
Using Saliva Epigenetic Data to Develop and Validate a Multivariable Predictor of Esophageal Cancer Status Open
Background: Salivary epigenetic biomarkers may detect esophageal cancer. Methods: A total of 256 saliva samples from esophageal adenocarcinoma patients and matched volunteers were analyzed with Illumina EPIC methylation arrays. Three datas…
View article: Development and validation of a multivariable risk factor questionnaire to detect oesophageal cancer in 2-week wait patients
Development and validation of a multivariable risk factor questionnaire to detect oesophageal cancer in 2-week wait patients Open
We have developed and validated a risk stratification tool using a questionnaire approach. This could aid prioritising patients at high risk of having oesophageal cancer for endoscopy. Our tool could help address endoscopic backlogs caused…
View article: PTU-24 The role of Hemospray as a monotherapy treatment of Gastrointestinal bleeds
PTU-24 The role of Hemospray as a monotherapy treatment of Gastrointestinal bleeds Open
Introduction Dual endoscopic therapy has been considered the standard of care for endoscopic management of GI bleeding. We aimed to look at the outcomes of Hemospray as a monotherapy treatment for GI bleeds. Methods Data was collected on p…
View article: Hemostatic powder TC‐325 treatment of malignancy‐related upper gastrointestinal bleeds: International registry outcomes
Hemostatic powder TC‐325 treatment of malignancy‐related upper gastrointestinal bleeds: International registry outcomes Open
Background and Aim Upper gastrointestinal tumors account for 5% of upper gastrointestinal bleeds. These patients are challenging to treat due to the diffuse nature of the neoplastic bleeding lesions, high rebleeding rates, and significant …
View article: P32 Use of Hemospray in the treatment of lower gastrointestinal bleeds: outcomes from the hemospray registry
P32 Use of Hemospray in the treatment of lower gastrointestinal bleeds: outcomes from the hemospray registry Open
Introduction Lower Gastrointestinal bleeding (LGIB) accounts for 20% of GI bleeds, with significant mortality in the elderly and those with comorbidities. There is limited data on the use of Hemospray in LGIB's. The primary aim was to look…
View article: P33 Hemospray treatment in non-variceal Upper Gastrointestinal bleeds: outcomes from the first 500 Hemospray registry patients
P33 Hemospray treatment in non-variceal Upper Gastrointestinal bleeds: outcomes from the first 500 Hemospray registry patients Open
Introduction Upper gastrointestinal bleeding (UGIB) is a leading cause of morbidity. The aim was to look at outcomes in patients with non-variceal UGIBs of all causes treated with Hemospray. Methods Data was collected prospectively (Jan' 1…
View article: P31 Hemospray in the treatment of variceal bleeds: outcomes from the international hemospray registry
P31 Hemospray in the treatment of variceal bleeds: outcomes from the international hemospray registry Open
Introduction Early treatment for variceal bleeding is recommended within 12 hours to improve outcomes. Endoscopic therapy in acute variceal bleeding can be technically difficult and not always successful and a bridge is sometimes required …
View article: Oral Hairy Leukoplakia Related to Orodispersible Budesonide Use
Oral Hairy Leukoplakia Related to Orodispersible Budesonide Use Open
CASE REPORT A 46-year-old nonsmoking man with a history of eosinophilic esophagitis (EoE), for which he was taking orodispersible budesonide 1 mg twice daily, presented with a painless, white plaque on his tongue (Figure 1). He had been ta…
View article: Outcomes of Hemospray therapy in the treatment of intraprocedural upper gastrointestinal bleeding post‐endoscopic therapy
Outcomes of Hemospray therapy in the treatment of intraprocedural upper gastrointestinal bleeding post‐endoscopic therapy Open
Introduction With increasing advances in minimally invasive endoscopic therapies and endoscopic resection techniques for luminal disease, there is an increased risk of post‐procedure bleeding. This can contribute to significant burden on p…
View article: Quality indicators for Barrett’s endotherapy (QBET): UK consensus statements for patients undergoing endoscopic therapy for Barrett’s neoplasia
Quality indicators for Barrett’s endotherapy (QBET): UK consensus statements for patients undergoing endoscopic therapy for Barrett’s neoplasia Open
Introduction Endoscopic therapy for the management of patients with Barrett’s oesophagus (BE) neoplasia has significantly developed in the past decade; however, significant variation in clinical practice exists. The aim of this project was…
View article: PTH-030 Outcomes of hemospray use in peptic ulcer upper gastrointestinal bleeds: Outcomes from the hemospray registry
PTH-030 Outcomes of hemospray use in peptic ulcer upper gastrointestinal bleeds: Outcomes from the hemospray registry Open
Introduction Peptic ulcers are the commonest cause of upper Gastrointestinal bleeding (UGIB). Hemospray (Cook Medical, North Carolina, USA) is a novel haemostatic powder aimed to treat UGIB. The aim of this study is to look at outcomes in …
View article: AWE-06 Outcomes of hemospray use in tumour related upper gastrointestinal bleeds: Outcomes from the hemospray registry
AWE-06 Outcomes of hemospray use in tumour related upper gastrointestinal bleeds: Outcomes from the hemospray registry Open
Introduction Patients with tumour related upper gastrointestinal bleeds (UGIBs) are challenging to treat. Hemospray (Cook Medical, North Carolina, USA) is a novel haemostatic powder for GI bleeding. The primary aim was to look at outcomes …
View article: 61 Prevalence of RAS/RAF mutations in pancreatic cystic lesions and correlation with malignant potential
61 Prevalence of RAS/RAF mutations in pancreatic cystic lesions and correlation with malignant potential Open
Background Incidence of pancreatic cystic lesions (PCL) is increasing due to ageing populations and increasing cross-sectional imaging. PCL are often benign but have potential for malignant transformation, particularly mucinous cysts. Sur…